

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

BioElectronics Corporation

A Maryland Corporation

4539 Metropolitan Court
 Frederick, MD 21704
 301-874-4890
 www.bielcorp.com
 info@bielcorp.com
 SIC Code: 3845

**Annual Report
 For the Period Ending: December 31, 2019
 (the "Reporting Period")**

As of December 31, 2019, the number of shares outstanding of our Common Stock was: 22,917,518,736

As of December 31, 2018, the number of shares outstanding of our Common Stock was: 20,706,218,020

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No: (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

None

¹ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable)
Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

BioElectronics Corporation was incorporated in the State of Maryland in April 2000 and remains as an active Corporation.

Has the issuer or any of its predecessors ever been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

2) Security Information

Trading symbol:	<u>BIEL</u>
Exact title and class of securities outstanding:	<u>Common stock</u>
CUSIP:	<u>09062H108</u>
Par or stated value:	<u>.001</u>
Total shares authorized:	<u>25,000,000,000</u> as of date: 12/31/2019
Total shares outstanding:	<u>22,917,518,737</u> as of date: 12/31/2019
Number of shares in the Public Float ² :	<u>20,000,000</u> as of date: 12/31/2019
Total number of shareholders of record:	<u>169</u> as of date: 12/31/2019

Additional class of securities (if any):

None

Transfer Agent

Name: Action Stock Transfer

Address 1: 2469 E. Fort Union Blvd., Suite 214

Address 2: Salt Lake City, UT 84121

Phone: 801 274 1088

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).		Reason for share issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
Number of Shares outstanding as of		<u>Opening Balance:</u>								
12/31/2018	Common:	20,706,218,020								
	Preferred:	N/A								
3/6/2018	New issuance	344,474,333	Common stock	0.00030	Yes	Riptide Capital LLC	Alan Stephen	Debt Conversion	Unrestricted	Exempt - Rule 144
7/9/2018	New issuance	20,000,000	Common stock	0.00030	Yes	john Martinez		Options Exercise	Unrestricted	Exempt - Rule 144
7/16/2018	New issuance	125,000,000	Common stock	0.00030	Yes	Riptide Capital LLC	Alan Stephen	Debt Conversion	Unrestricted	Exempt - Rule 144
7/16/2018	New issuance	5,000,000	Common stock	0.00035	Yes	Lucas Tatem		Options Exercise	Unrestricted	Exempt - Rule 144
7/17/2018	New issuance	323,855,032	Common stock	0.00015	Yes	Richard Staelin Trust	Richard Staelin	Debt Conversion	Unrestricted	Exempt - Rule 144
10/1/2018	New issuance	315,150,185	Common stock	0.00043	Yes	eMarkets Group	Mary Nyary	Debt Conversion	Unrestricted	Exempt - Rule 144
10/15/2018	New issuance	100,000,000	Common stock	0.00125	Yes	Keith Nalepka		Services	Unrestricted	Exempt - Rule 144
10/26/2018	New issuance	276,988,888	Common stock	0.00030	Yes	Tiger Trout Capital	Alan Stephen	Debt Conversion	Unrestricted	Exempt - Rule 144
11/29/2018	New issuance	118,177,520	Common stock	0.00058	Yes	Deepak Kotak		Debt Conversion	Unrestricted	Exempt - Rule 144
11/29/2018	New issuance	85,909,350	Common stock	0.00049	Yes	Deepak Kotak		Debt Conversion	Unrestricted	Exempt - Rule 144
2/25/2019	New issuance	284,844,444	Common stock	0.00080	Yes	IBEX	Kelly A. Whelan	Debt Conversion	Unrestricted	Exempt - Rule 144
2/28/2019	New issuance	173,651,367	Common stock	0.00140	Yes	Jarencz	Lauren Jarman	Debt Conversion	Unrestricted	Exempt - Rule 144
3/22/2019	New issuance	217,222,667	Common stock	0.00090	Yes	IBEX	Kelly A. Whelan	Debt Conversion	Unrestricted	Exempt - Rule 144
3/22/2019	New issuance	236,367,779	Common stock	0.00080	Yes	IBEX	Kelly A. Whelan	Debt Conversion	Unrestricted	Exempt - Rule 144
5/16/2019	New issuance	131,432,000	Common stock	0.00070	Yes	Tiger Trout Capital	Alan Masley	Debt Conversion	Unrestricted	Exempt - Rule 144
6/14/2019	New issuance	233,333,333	Common stock	0.00080	Yes	Green Coast Capital	Ed Liceaga	Debt Conversion	Unrestricted	Exempt - Rule 144
8/5/2019	New issuance	464,908,667	Common stock	0.00030	Yes	Jarman	Lauren Jarman	Debt Conversion	Unrestricted	Exempt - Rule 144
9/10/2019	New issuance	469,540,459	Common stock	0.00050	Yes	Richard Staelin	Richard Staelin	Debt Conversion	Unrestricted	Exempt - Rule 144
Number of Shares outstanding as of		<u>Ending Balance:</u>								
12/31/2019	Common:	22,917,518,736								
	Preferred:	N/A								

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Debt Outstanding as of December 31, 2019, issued before 2019

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
8/1/19-12/14/17	\$ 6,012,107	\$ 5,891,671	\$ 120,436	1/30/20-12/25/21	Convertible into shares at prices approx. 50% of market price at issue date	IBEX	Operating Loans
11/9/10-9/1/17	\$ 729,785	\$ 456,586	\$ 273,199	3/16/20-12/21/21		R. Staelin	Operating Loans
11/30/12-12/31/17	\$ 3,371,958	\$ 2,017,504	\$ 1,354,454	3/26/20-12/31/21		St. John's	Operating Loans
9/30/2013	\$ 11,928	\$ 12,848	\$ -	9/30/2021		M. Whelan	Operating Loan
5/16/2015	\$ 475,698	\$ 500,000	\$ -	11/15/2023		None	Ex-Im Bank
1/8/2018	\$ 34,941	\$ 30,000	\$ 4,941	1/8/2020	Convertible into shares at prices approx. 50% of market price at issue date	IBEX	Operating Loan
2/7/2018	\$ 58,602	\$ 50,633	\$ 7,969	2/7/2020		R. Staelin	Operating Loan
3/31/2018	\$ 42,941	\$ 37,500	\$ 5,441	3/31/2020		St. John's	Operating Loan
3/31/2018	\$ 82,447	\$ 72,000	\$ 10,447	3/31/2020		McLeod	Operating Loan
5/1/18	\$ 228,042	\$ 200,000	\$ 28,042	5/1/2020		T. Kim	Operating Loan
5/8/18	\$ 181,776	\$ 160,000	\$ 21,776	5/8/2020		A. Humar	Operating Loan
5/21/18	\$ 152,958	\$ 135,000	\$ 17,958	5/21/2020		J. Eason	Operating Loan
6/30/18	\$ 42,134	\$ 37,500	\$ 4,634	6/30/2020		St. John's	Operating Loan
6/30/18	\$ 141,900	\$ 126,000	\$ 15,900	6/30/2020		R. Staelin	Operating Loan
7/13/18	\$ 88,274	\$ 79,000	\$ 9,274	7/13/2020		Jarman	Operating Loan
9/24/18	\$ 15,280	\$ 13,869	\$ 1,411	9/24/2020		R. Staelin	Operating Loan
9/30/18	\$ 27,544	\$ 25,000	\$ 2,544	9/30/2020		St. John's	Operating Loan
11/1/18	\$ 180,544	\$ 165,000	\$ 15,544	11/1/2020		Convertible into shares at prices approx. 50% of market price at issue date	Jarman
11/29/18	\$ 54,367	\$ 50,000	\$ 4,367	11/29/2020	St. John's		Operating Loan

B. Debt Securities, Including Promissory and Convertible Notes (Continued)

Debt Outstanding as of December 31, 2019, issued in 2019

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)	
2/5/2019	\$ 10,519	\$ 10,000	\$ 519	2/5/2021	Convertible into shares at prices approx. 50% of market price at issue date	R. Staelin	Operating Loan	
2/19/2019	\$ 53,451	\$ 50,000	\$ 3,451	2/19/2021		Jarman	Operating Loan	
3/1/2019	\$ 53,353	\$ 50,000	\$ 3,353	3/1/2021		IBEX	Operating Loan	
3/8/2019	\$ 53,232	\$ 50,000	\$ 3,232	3/8/2021		Jarman	Operating Loan	
3/27/2019	\$ 53,057	\$ 50,000	\$ 3,057	3/27/2021		IBEX	Operating Loan	
3/31/2019	\$ 26,507	\$ 25,000	\$ 1,507	3/31/2021		St. John's	Operating Loan	
5/1/2019	\$ 8,429	\$ 8,000	\$ 429	5/1/2021		St. John's	Operating Loan	
5/28/19	\$ 41,903	\$ 40,000	\$ 1,903	5/28/2021		Jarman	Operating Loan	
5/29/19	\$ 94,702	\$ 200,000	\$ -	5/29/2020		None	WebBank	Operating Loan
6/2/19	\$ 10,417	\$ 10,000	\$ 417	6/2/2021		Convertible into shares at prices approx. 50% of market price at issue date	Jarman	Operating Loan
7/1/19	\$ 36,412	\$ 35,000	\$ 1,412	7/1/2021	St. John's		Operating Loan	
8/8/19	\$ 61,394	\$ 60,000	\$ 1,394	8/8/2021	St. John's		Operating Loan	
8/30/19	\$ 30,408	\$ 30,000	\$ 408	8/30/2021	St. John's		Operating Loan	
9/20/19	\$ 23,421	\$ 50,000	\$ -	2/29/2020	None	Fox Capital	Operating Loan	
10/1/19	\$ 48,968	\$ 48,000	\$ 968	10/1/2021	Convertible into shares at prices approx. 50% of market price at issue date	R. Staelin	Operating Loan	
10/17/19	\$ 16,263	\$ 16,000	\$ 263	10/17/2021		IBEX	Operating Loan	
10/24/19	\$ 50,745	\$ 50,000	\$ 745	10/24/2021		Jarman	Operating Loan	
11/7/19	\$ 20,237	\$ 20,000	\$ 237	11/7/2021		M. Whelan	Operating Loan	
11/26/19	\$ 15,115	\$ 15,000	\$ 115	11/26/2021		M. Whelan	Operating Loan	
11/29/19	\$ 15,105	\$ 15,000	\$ 105	11/29/2021		M. Whelan	Operating Loan	
12/10/19	\$ 40,184	\$ 40,000	\$ 184	12/10/2021		R. Staelin	Operating Loan	
12/20/19	\$ 100,362	\$ 100,000	\$ 362	12/20/2021	T. Kim	Operating Loan		

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Brian Flood
Title: CPA
Relationship to Issuer: Contractor, through Consult Your CFO, Inc.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Changes in Shareholders' Equity
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

The financial statements for the year ended December 31, 2019 were posted to OTCIQ on April 02, 2020 with the file name: BioElectronics BIEL OTC Financials 2019 15March2020 IAD

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

In February 2017, BioElectronics announced that it received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee. On July 1, 2019 the Company announced that it has received market clearance from the United States Food and Drug Administration (US FDA) for its RecoveryRx® medical device, for the treatment of postoperative pain.

In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch® medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.

The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company's medical devices modulate the body's nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.

Ken McLeod, PhD. Director of Clinical Science and Engineering Research, Binghamton State University of New York, explains in a short video how the technology and ActiPatch works at <http://actipatch.com/why-actipatch/>. The technology

has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics' technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

None

C. Describe the issuers' principal products or services, and their markets

Our current OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for our flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use.

The Company has focused attention on international customers to expand its distributions and sales. The Company has established distribution agreements with distributors in the United Kingdom, Sweden, Southeast Asia, Canada, Australia, Spain, Italy and Austria. The distribution agreements grant the right to sell BioElectronics' products in certain territories. The distributors are responsible for advertising and promotion in their assigned territories. In addition, the distributors are subject to minimum annual product purchases, minimum initial purchases, and minimum inventory requirements.

The United Kingdom's National Health Services has recently reduced its funding for hip and knee replacement surgeries. We anticipate the restoration of this budget allowance in the near future.

The transfer of our UK over-the-counter product sales to reimbursable prescription sales behind the pharmacy counter mandates that the customer obtain a prescription from their assigned physician. As a prescription product, ActiPatch is available for free to 80 to 90% of the population in all 14,000 pharmacies. ActiPatch therapy has proven to be successful for managed care providers, with clinical economic evidence of a 58% reduction in office visits and a 36% reduction in medication costs, and an overall 41% saving in chronic pain sufferers' costs.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company is headquartered, manages and operates its business at 4539 Metropolitan Court, Frederick, MD 21704 USA. The Company presently leases 4,100 sq. ft of space. The lease commenced on November 1, 2008, and is currently on a month-to-month lease.

The main office consists of seven (7) offices, a conference room and reception area to accommodate staff and complete business activities. A separate area of space is dedicated to product, storage, packaging, machines, tables, and shipping supplies. It is well equipped with desks, computers, furniture, chairs, telephones, printers, copier, fax machine, cabinets and office supplies. The Company owns all furniture and fixtures.

7) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, regardless of the number of shares they own. **If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.**

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Kelly Whelan</u>	<u>President</u>	<u>Ashburn, VA</u>	<u>37,333,033</u>	<u>Common Stock</u>	<u>N/A</u>	_____
<u>Patricia Whelan</u>	<u>Director</u>	<u>Frederick, MD</u>	<u>350,000,000</u>	<u>Common Stock</u>	<u>N/A</u>	_____
<u>John Martinez</u>	<u>VP of Engineering</u>	<u>Thurmont, MD</u>	<u>32,500,000</u>	<u>Common Stock</u>	<u>N/A</u>	<u>Resigned as officer 2/7/20</u>
<u>Keith Nalepka</u>	<u>VP of Sales & Marketing</u>	<u>Leesburg, VA</u>	<u>100,000,000</u>	<u>Common Stock</u>	<u>N/A</u>	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

Pursuant to a CORRECTED ORDER MAKING FINDINGS AND IMPOSING REMEDIAL SANCTIONS AND A CEASE-AND-DESIST ORDER PURSUANT TO SECTION 8A OF THE SECURITIES ACT OF 1933 AND SECTIONS 15(b) AND 21C OF THE SECURITIES EXCHANGE ACT OF 1934 entered on December 21, 2018 and served to her counsel Corrigan and Morris on April 22, 2019, Kelly Whelan is, barred, for a period of 1 year, from participating in an offering of penny stock, including engaging in activities with a broker, dealer, or issuer for purposes of issuing, trading, or inducing or attempting to induce the purchase or sale of any penny stock. A penny stock is any equity security that has a price of less than five dollars, except as provided in Rule 3a51-1 under the Exchange Act [17 C.F.R. 240.3a51-1].

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

In February 2016, the Securities and Exchange Commission instituted a public administrative and cease-and-desist proceedings, pursuant to Section 8A of the Securities Act of 1933 against the Company, its late President, and IBEX, LLC, owned by the now deceased President's daughter Kelly Whelan, a major debtholder. The SEC objected to IBEX's stock and convertible note sales and the reinvestment of proceeds back into the Company. Ibex maintained that all note and stock sales were to qualified investors in accordance with SEC Rule 144, held for longer than the SEC mandated holding period, and were supported by proper legal opinions. The SEC argued that BioElectronics and IBEX, LLC were under the common control of Andrew Whelan and Kelly Whelan which invalidated the Rule 144 exemption. Additionally, the SEC asserted improper timing of two sales transactions in the audited fiscal year 2009 financial statements

In both the initial trial and the Supreme Court ordered retrial the SEC's Administrative Law Judge issued an Initial Decision recommending disgorgement and penalties. He has also recommended a Penny Stock Bar against Andrew Whelan and Kelly Whelan.

Administrative Law Judges' Decisions must be concluded by the SEC Commissioners. The SEC Commissioners have never approved the Decision. Shortly thereafter, the Division of Enforcement and Respondents reached a settlement in principle, in lieu of the unique procedural circumstances that would require a rehearing of this matter, which the Division of Enforcement recommends that the Commission approve. Accordingly, on September 14, 2018, the parties jointly requested a stay of these proceedings, which ALJ Grimes granted.

Pursuant to a CORRECTED ORDER MAKING FINDINGS AND IMPOSING REMEDIAL SANCTIONS AND A CEASE-AND-DESIST ORDER PURSUANT TO SECTION 8A OF THE SECURITIES ACT OF 1933 AND SECTIONS 15(b) AND 21C OF THE SECURITIES EXCHANGE ACT OF 1934 entered on December 21, 2018 and served to counsel Corrigan and Morris on April 22, 2019, Respondents BioElectronics, IBEX, A. Whelan, and K. Whelan shall, pay jointly and severally, disgorgement of \$166,640 to the Securities and Exchange Commission for transfer to the general fund of the United States Treasury, subject to Exchange Act Section 21F(g)(3), as follows: (i) within 30 days of the entry of this Order, \$16,640; (ii) within 180 days of the entry of this Order, \$16,640; and (iii) within 365 days of the entry of this Order, \$133,360. If timely payment is not made, additional interest shall accrue pursuant to SEC Rule of Practice 600. G. Respondents BioElectronics, St. John's, and A. Whelan shall, pay jointly and severally, disgorgement of \$25,000 to the Securities and Exchange Commission for transfer to the general fund of the United States Treasury, subject to Exchange Act Section 21F(g)(3), as follows: (i) within 30 days of the entry of this Order, \$2,500; (ii) within 180 days of the entry of this Order, \$2,500; and (iii) within 365 days of the entry of this Order, \$20,000. If timely payment is not made, additional interest shall accrue pursuant to SEC Rule of Practice 600.

BioElectronics received notice in June 2019 that Endonovo Therapeutics, Inc. filed a lawsuit against BioElectronics in the United States District Court for the Central District of California. The lawsuit asserts that BioElectronics' ActiPatch® medical device infringes Endonovo's US Patent Nos. 7,740,574 and 7,758,490. The lawsuit requests relief that is characteristic of patent infringement lawsuits, including damages and injunctive relief.

BioElectronics has been a leader in the non-thermal shortwave therapy landscape since 2001, and has carefully developed its proprietary technology and innovative products while respecting the intellectual property rights of competitors, including those of Endonovo. The case was voluntarily dismissed in November 2019 without prejudice.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Robert Sonfield
Firm: Sonfield & Sonfield
Address 1: 2500 Wilcrest, 3rd Floor
Address 2: Houston, TX 77042
Phone: 713-877-8333
Email: robert@sonfield.com

Accountant or Auditor

Name: Brian P. Flood
Firm: Consult Your CFO
Address 1: 1680 Nickerson Way
Address 2: Arnold, MD 21012
Phone: 443-838-6352
Email: bflood@cfochesapeake.com

Investor Relations

Name: Paul Knopick
Firm: E & E Communications
Address 1: 8604 Gardenia Drive
Address 2: Denton, Texas 76207
Phone: 940-262-3584
Email: ir@bielcorp.com

Other Service Providers

Provide the name of any other service provider(s) **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: Aaron Koheis
Firm: Shulman & Rogers
Nature of Services: Legal
Address 1: 12505 Park Avenue
Address 2: Potomac, MD 20854
Phone: 301-230-5200
Email: info@shulmanrogers.com

10) Issuer Certification

Principal Executive Officer

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format below:

I, Kelly Whelan, certify that:

1. I have reviewed this annual disclosure statement of BioElectronics, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

04/02/2020 [Date]

/s/ Kelly Whelan [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Kelly Whelan, certify that:

1. I have reviewed this annual disclosure statement of BioElectronics, Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

04/02/2020 [Date]

/s/ Kelly Whelan [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")